Purpose Recent years have seen a change in the way that clinical trials are being
conducted. There has been a rise of designs more flexible than traditional adaptive and …

Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic
tendency for the estimate of treatment effect to deviate from its true value,” and states that it is …

Adaptive designs for clinical trials permit alterations to a study in response to accumulating
data in order to make trials more flexible, ethical, and efficient. These benefits are achieved …

The COVID-19 pandemic has led to an unprecedented response in terms of clinical
research activity. An important part of this research has been focused on randomized …

Abstract Response-Adaptive Randomization (RAR) is part of a wider class of data-
dependent sampling algorithms, for which clinical trials are typically used as a motivating …

Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic
tendency for the estimate of treatment effect to deviate from its true value”, and states that it is …

A Bayesian group sequential design is proposed that performs survival comparisons within
patient subgroups in randomized trials where treatment–subgroup interactions may be …

Estimating the maximum mean finds a variety of applications in practice. In this paper, we
study estimation of the maximum mean using an upper confidence bound (UCB) approach …

Response-adaptive randomization allows the probabilities of allocating patients to
treatments in a clinical trial to change based on the previously observed response data, in …

Recent FDA guidance on adaptive clinical trial designs defines bias as" a systematic
tendency for the estimate of treatment effect to deviate from its true value", and states that it is …